| Identification | Back Directory | [Name]
(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID | [CAS]
89396-94-1 | [Synonyms]
Novarok
SH-6366
Novaloc
TA 6366
Tanapril
Tanatril
ACE/TA-6366
IMipadril HCl
Imidaprilhydrochloride
Imidapril HCl (TA-6366)
ImidaprilHydrochloride>
Imidapril monohydrochloride
Imidapril hydrochloride [jan]
Imidapril Hydrochloride (cGMP)
IMidapril Hydrochloride USP/EP/BP
IMidapril HCL & its interMediates
Imidapril Hydrochloride (secondary standard)
(-)-(4S)-3-[2(S)-[N-[1(S)-(Ethoxycarbonyl)-3-phenylpropyl]am...
(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID
(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID USP/EP/BP
(S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride
(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID: HYDROCHLORIDE
3-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid hydrochloride
(4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid,hydrochloride
(-)-(4S)-3-[2(S)-[N-[1(S)-(Ethoxycarbonyl)-3-phenylpropyl]amino]propionyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride
4-Imidazolidinecarboxylicacid,3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-,hydrochloride (1:1)
4-IMidazolidinecarboxylicacid,3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]aMino]-1-oxopropyl]-1-Methyl-2-oxo-,hydrochloride (1:1), (4S)-
4-Imidazolidinecarboxylic acid, 3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, monohydrochloride, (4S)-
4-Imidazolidinecarboxylic acid, 3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, monohydrochloride, [4S-[3[R*(R*)],4R*]]- | [EINECS(EC#)]
685-551-0 | [Molecular Formula]
C20H27N3O6 | [MDL Number]
MFCD00923828 | [MOL File]
89396-94-1.mol | [Molecular Weight]
405.445 |
| Chemical Properties | Back Directory | [Melting point ]
214-216℃ | [alpha ]
D20 -64.1° (c = 0.5 in ethanol) | [storage temp. ]
?20°C | [solubility ]
H2O: ≥5mg/mL | [form ]
powder | [color ]
white to tan | [optical activity]
[α]/D -50 to -70° in ethanol (c=0.5) | [Merck ]
14,4911 |
| Hazard Information | Back Directory | [Uses]
antibiotic | [Definition]
ChEBI: Imidapril hydrochloride is a dipeptide. | [General Description]
Imidapril comprises large acyl moiety and is hydrolyzed by carboxylesterase (CES) 1. | [Biochem/physiol Actions]
Imidapril is a potent angiotensin converting enzyme inhibitor and anti-hypertensive. | [Clinical Use]
Angiotensin-converting enzyme inhibitor:
Hypertension | [Drug interactions]
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and
increased risk of renal impairment with NSAIDs;
hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia,
hypotension and renal failure with ARBs and
aliskiren.
Bee venom extract: possible severe anaphylactoid
reactions when used together.
Ciclosporin: increased risk of hyperkalaemia and
nephrotoxicity.
Cytotoxics: increased risk of angioedema with
everolimus.
Diuretics: enhanced hypotensive effect;
hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism
of hypotensive effect.
Gold: flushing and hypotension with sodium
aurothiomalate.
Lithium: reduced excretion, possibility of enhanced
lithium toxicity.
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and
nephrotoxicity. | [Metabolism]
Imidapril is a prodrug, and is metabolised in the liver
to the diacid imidaprilat, its active metabolite. The
bioavailability of imidaprilat is about 42% after oral doses
of imidapril.
About 40% of an oral dose is excreted in the urine, the
rest in the faeces. |
|
|